OKYO Pharma Ltd Schedule 13G: Sirenia Capital Management and Alex Silverstein report joint beneficial ownership of 4,054,054 Ordinary Shares, representing 7.7% of the class.
OKYO Pharma Ltd Schedule 13G: Sirenia Capital Management and Alex Silverstein report joint beneficial ownership of 4,054,054 Ordinary Shares, representing 7.7% of the class. The filing bases the percentage on 52,479,257 Ordinary Shares outstanding as calculated from issuer disclosures.
The filing states the Sirenia Fund holds the shares and has the right to receive dividends or proceeds on more than 5% of the class. Ownership is reported as shared voting and dispositive power of 4,054,054 shares.
Positive
None.
Negative
None.
Insights
Sirenia reports a 7.7% passive stake via a managed fund.
Sirenia Capital Management and its managing member, Alex Silverstein, report shared voting and shared dispositive power over 4,054,054 shares. The statement is filed on behalf of SILV Fund, Ltd., the investment vehicle that holds the shares.
Percentage ownership references an aggregate base of 52,479,257 Ordinary Shares; timing and source components are cited from the issuer's prospectus and a March 12, 2026 6-K. Future filings would show any material changes in position.
The filing is a Rule 13d-1(k) joint disclosure showing passive beneficial ownership.
The Reporting Persons state they filed jointly under a Joint Filing Agreement and disclaim admission of beneficial ownership for Section 13 purposes. The Sirenia Fund is identified as the holder with rights to dividends/proceeds exceeding 5%.
Signature lines show authorized signatories; Exhibit 99.1 is the joint filing agreement. This is a disclosure of current holdings, not an acquisition or disposition notice.
Key Figures
Shares beneficially owned:4,054,054 sharesPercent of class:7.7%Shares outstanding (aggregate):52,479,257 shares+3 more
6 metrics
Shares beneficially owned4,054,054 sharesReported beneficial ownership by Sirenia/SILV Fund
Percent of class7.7%Percent of Ordinary Shares based on aggregate outstanding
Shares outstanding (aggregate)52,479,257 sharesAggregate used to calculate percentage ownership
Offering shares (component)10,815,000 sharesIssued in offering referenced from March 12, 2026 6-K
Underwriter overallotment1,109,060 sharesIssued pursuant to exercise of underwriters' option per March 12, 2026 6-K
Outstanding as of40,555,197 sharesReported outstanding as of <date>February 9, 2026</date>
"This statement is filed by: (i) Sirenia Capital Management LP ..."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficial ownershipfinancial
"Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared dispositive powerregulatory
"Shared Dispositive Power 4,054,054.00"
Joint Filing Agreementlegal
"Sirenia and Mr. Silverstein have entered into a Joint Filing Agreement"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Sirenia Capital report in OKYO (OKYO)?
Sirenia Capital and Alex Silverstein report beneficial ownership of 4,054,054 shares, equal to 7.7% of OKYO's Ordinary Shares, based on an aggregate of 52,479,257 outstanding shares used for the percentage calculation.
How was the outstanding share count determined in the Schedule 13G?
The percentage uses an aggregate of 52,479,257 Ordinary Shares, combining 10,815,000 shares from the issuer's offering, 1,109,060 from the underwriters' option, and 40,555,197 reported as outstanding as of February 9, 2026.
Does Sirenia have voting control over the reported OKYO shares?
The filing reports shared voting power and shared dispositive power over 4,054,054 shares; sole voting and sole dispositive powers are reported as zero on the cover rows cited in the statement.
Is the Schedule 13G filing an admission of beneficial ownership under Section 13?
The Reporting Persons expressly state the filing "should not be construed as an admission" that any of them is the beneficial owner for Section 13 purposes and the filing is made jointly under a Joint Filing Agreement filed as Exhibit 99.1.
Who filed the Schedule 13G for OKYO and who signed it?
The statement is filed by Sirenia Capital Management (on behalf of SILV Fund, Ltd.) and Alex Silverstein. Signatures include Kolby Loft, General Counsel & Chief Compliance Officer, and Alex Silverstein, dated 05/15/2026.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
OKYO Pharma Ltd
(Name of Issuer)
Ordinary Shares, without par value
(Title of Class of Securities)
G6724L116
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
G6724L116
1
Names of Reporting Persons
Sirenia Capital Management LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,054,054.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,054,054.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,054,054.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.7 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
G6724L116
1
Names of Reporting Persons
Alex Silverstein
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,054,054.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,054,054.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,054,054.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.7 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
OKYO Pharma Ltd
(b)
Address of issuer's principal executive offices:
9th Floor, 107 Cheapside, London EC2V 6DN
Item 2.
(a)
Name of person filing:
This statement is filed by:
(i) Sirenia Capital Management LP ("Sirenia") with respect to the ordinary shares, without par value ("Ordinary Shares"), of OKYO Pharma Ltd (the "Issuer") held by SILV Fund, Ltd. (the "Sirenia Fund"), an investment fund it manages; and
(ii) Alex Silverstein ("Mr. Silverstein"), the managing member of Sirenia Capital Management GP LLC, the general partner of Sirenia, with respect to the Ordinary Shares held by the Sirenia Fund.
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
Sirenia and Mr. Silverstein have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act").
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of Sirenia and Mr. Silverstein is 1674 Meridian Avenue, Suite 320, Miami Beach, FL 33139.
(c)
Citizenship:
Sirenia is a Delaware limited partnership. Mr. Silverstein is a United States citizen.
(d)
Title of class of securities:
Ordinary Shares, without par value
(e)
CUSIP Number(s):
G6724L116
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 52,479,257 Ordinary Shares outstanding, which is the sum of (i) 10,815,000 Ordinary Shares issued in the offering described in the Issuer's Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission (the "SEC") on March 12, 2026 (the "March 12th 6-K"); (ii) 1,109,060 Ordinary Shares issued pursuant to the exercise of the underwriters' overallotment option as reported in the March 12th 6-K; and (iii) 40,555,197 Ordinary Shares outstanding as of February 9, 2026, as reported in the Issuer's Prospectus filed pursuant to Rule 424(b)(5) with the SEC on February 17, 2026.
(b)
Percent of class:
7.7%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a). The Sirenia Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Ordinary Shares.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Sirenia Capital Management LP
Signature:
/s/ Kolby Loft
Name/Title:
Kolby Loft, General Counsel & Chief Compliance Officer
